Rezolute Inc. (RZLT)
NASDAQ
Closed
Sep 21, 2026
Day's Range
3.7352 wk Range
1.07Overview - RZLT - Rezolute Inc.
Key Statistics
Valuation
Enterprise Value
282.38M
P/E (Trailing)
‪-4.29‬
P/E (Forward)
‪-6.73‬
PEG Ratio
‪0.10‬
Price / Book
‪3.77‬
EV / EBITDA
‪-3.29‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-48.73%‬
Return on Equity
‪-81.72%‬
Ownership
Shares Outstanding
96.29M
Float
60.48M
Short % of Shares Outstanding
‪26.58%‬
Held by Insiders
‪10.15%‬
Held by Institutions
‪98.78%‬
Price stats
Beta
‪0.61‬
50-Day Avg
‪4.76‬
200-Day Avg
‪4.04‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
10 analysts
Average price target
‪$ 7.67‬Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - RZLT - Rezolute Inc.
Peers - RZLT - Rezolute Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- RZLTNASDAQRezolute Inc.406.35MMarket Cap-77.01%52-week change-4.30P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQArgenx SE61.58BMarket Cap+25.27%52-week change37.92P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.32.05BMarket Cap-91.57%52-week change41.68P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE24.13BMarket Cap-2.77%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S15.57BMarket Cap+17.02%52-week change18.34P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.02BMarket Cap+22.62%52-week change-17.62P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.12.37BMarket Cap+15.64%52-week change172.81P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - RZLT - Rezolute Inc.
About
Rezolute Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases associated with chronic glucose imbalance. Its lead program centers on ersodetug, an intravenously administered human monoclonal antibody being studied for congenital hyperinsulinism and other…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
